(Q30857226)

27 June 2017

title

Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neck (English)

1 reference

27 June 2017

main subject

head and neck carcinoma

1 reference

S J Clarke

1

1 reference

27 June 2017

J Zalcberg

2

1 reference

27 June 2017

I Olver

3

1 reference

27 June 2017

P L Mitchell

4

1 reference

27 June 2017

D Rischin

5

1 reference

27 June 2017

D Dalley

6

1 reference

27 June 2017

M Green

7

1 reference

27 June 2017

Y E Davidson

8

1 reference

27 June 2017

publication date

1 February 2000

1 reference

27 June 2017

1 reference

27 June 2017

volume

11

1 reference

27 June 2017

issue

2

1 reference

27 June 2017

page(s)

239-241

1 reference

27 June 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

1 reference

7 January 2021

Mature results from three large controlled studies with raltitrexed ('Tomudex').

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

7 January 2021

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

7 January 2021

Assessment of response to therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

7 January 2021

Chemotherapy of cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

7 January 2021

5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

7 January 2021

A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

7 January 2021

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

7 January 2021

A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008369629944

7 January 2021

Identifiers

DOI

10.1023/A:1008369629944

1 reference

27 June 2017

1 reference